PharmaResources (Shanghai) Valuation

Is 301230 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 301230 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 301230 (CN¥24.88) is trading above our estimate of fair value (CN¥4.1)

Significantly Below Fair Value: 301230 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 301230?

Key metric: As 301230 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 301230. This is calculated by dividing 301230's market cap by their current revenue.
What is 301230's PS Ratio?
PS Ratio	6.7x
Sales	CN¥513.91m
Market Cap	CN¥3.42b

301230 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.3x
Enterprise Value/EBITDA	6848.5x
PEG Ratio	9.7x

Price to Sales Ratio vs Peers

How does 301230's PS Ratio compare to its peers?

The above table shows the PS ratio for 301230 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	8.9x
688238 Obio Technology (Shanghai)	14.1x	22.8%	CN¥3.5b
688222 HitGen	11.4x	19.4%	CN¥4.8b
688315 Novogene	2.5x	17.5%	CN¥5.2b
300813 Zhejiang Tailin BioEngineeringLtd	7.6x	n/a	CN¥2.3b
301230 PharmaResources (Shanghai)	6.7x	20.9%	CN¥3.4b

Price-To-Sales vs Peers: 301230 is good value based on its Price-To-Sales Ratio (6.7x) compared to the peer average (8.9x).

Price to Sales Ratio vs Industry

How does 301230's PS Ratio compare vs other companies in the CN Life Sciences Industry?

0 Companies	Price / Sales	Estimated Growth	Market Cap

No more companies available in this PS range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 301230 is expensive based on its Price-To-Sales Ratio (6.7x) compared to the CN Life Sciences industry average (4.9x).

Price to Sales Ratio vs Fair Ratio

What is 301230's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

301230 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	6.7x
Fair PS Ratio	3.7x

Price-To-Sales vs Fair Ratio: 301230 is expensive based on its Price-To-Sales Ratio (6.7x) compared to the estimated Fair Price-To-Sales Ratio (3.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

-4.2%

-23.6%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

-3.9%

12.1%

Hunan Jiudian Pharmaceutical

CN¥11.5b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.19

-2.6%

13.6%